Cencora, Inc. Announces Share Repurchase Agreement with Walgreens Boots Alliance Holdings LLC

Cencora, Inc. (NYSE: COR) recently disclosed in a Form 8-K filing with the Securities and Exchange Commission that it has entered into a significant share repurchase agreement with Walgreens Boots Alliance Holdings LLC. The transaction, finalized on February 10, 2025, involved Cencora repurchasing 204,491 shares of its common stock directly from the Selling Stockholder for an approximate total of $50 million. The repurchase was conducted under the company’s share repurchase program, with the acquired shares earmarked to be held in treasury.

The Share Repurchase Agreement highlights that the price per share paid by Cencora matched the price at which the Selling Stockholder had sold shares of Common Stock through the Rule 144 Sale. The agreement details were filed as Exhibit 10.1 to the Form 8-K filing, providing a comprehensive view of the specifics of the transaction.

At the same time, the Selling Stockholder engaged in early settlements of several variable prepaid forward sale contracts with financial institutions, along with the return of some shares of Common Stock pledged to those institutions as part of the contracts. Additionally, the Selling Stockholder executed a sale of 1,081,885 shares of Common Stock under Rule 144 of the Securities Act of 1933. Following these activities, the Selling Stockholder retained ownership of 12,570,000 shares of Common Stock, representing approximately 6.5% of the total outstanding shares of Common Stock of Cencora.

The Selling Stockholder’s remaining ownership stake in Cencora’s Common Stock remains pledged to financial institutions to ensure compliance with existing variable prepaid forward sale contracts. This move solidifies Cencora’s commitment to financial stability and strategic stock management.

About Cencora, Inc.
Cencora is a prominent global pharmaceutical solutions company dedicated to enhancing the quality of life for individuals and animals worldwide. The organization collaborates with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Cencora’s extensive global team focuses on delivering pharmaceuticals, healthcare products, and solutions reliably and securely. With a workforce of over 46,000 team members globally, Cencora reinforces its dedication to positive health outcomes via its mission of creating healthier futures. The company is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500, boasting annual revenue exceeding $290 billion.

The Form 8-K filing offers a glimpse into Cencora’s strategic moves to maintain operational excellence and financial strength in the evolving market landscape.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Cencora’s 8K filing here.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.